The antibiotic Ketek should no longer be used for the treatment of sinusitis and bronchitis, the U.S. Food and Drug Administration (FDA) is warning patients and health care providers. The new warnings came as part of an FDA announcement of changes to Ketek’s label, including stonger warnings regarding the drug’s side effects, and the addition of a “black box” warning stating that Ketek should not be used to treat patients who have myasthenia gravis, a condition that causes muscle weakness. The FDA continues to approve the use of Ketek in treatment of patients with pneumonia. Ketek is manufactured by Sanofi Aventis, and was originally approved by the FDA in 2004.
- Read the FDA Press Release
- Ketek Information and Resources (FindLaw)
You Don’t Have To Solve This on Your Own – Get a Lawyer’s Help
Civil Rights
Block on Trump’s Asylum Ban Upheld by Supreme Court
Criminal
Judges Can Release Secret Grand Jury Records
Politicians Can’t Block Voters on Facebook, Court Rules
